Intracranial aneurysms are common, and the risk of rupture is influenced by size, location, morphology, and factors such as ...

To access our most recent research and articles on Covid-19 and Covid-19 vaccines, please visit the NEJM Coronavirus (Covid-19) page. To realize the potential of recently developed Covid-19 ...

The case description for a Case Records of the Massachusetts General Hospital appears below. A 61-year-old man presented with hypoxemic respiratory failure and shock 10 weeks after kidney ...

In a double-blind, randomized, placebo-controlled trial in Zimbabwe, we assigned pregnant women to receive trimethoprim–sulfamethoxazole, at a dose of 960 mg daily, or placebo from at least 14 ...

The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it is also beneficial for ...

A total of 415 patients were assigned to cemiplimab (209) or placebo (206). The median follow-up was 24 months. Cemiplimab was superior to placebo with respect to disease-free survival (24 vs. 65 ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Dr. Ignacio Lopez Saubidet: A 52-year-old man presented to the emergency department of Centro de Educación Médica e Investigaciones Clínicas (CEMIC) in Buenos Aires in early autumn with fever ...

Among 494 patients who had undergone randomization, overall survival was significantly longer with trastuzumab deruxtecan than with ramucirumab plus paclitaxel (median, 14.7 vs. 11.4 months ...

Chinese obesity guidelines recommend pharmacotherapy for adults with obesity or with overweight accompanied by weight-related coexisting conditions if lifestyle interventions fail to control body ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who had received one ...